Trial Title:
National Network Genomic Medicine Lung Cancer, Germany
NCT ID:
NCT05934032
Condition:
Carcinoma, Non-Small-Cell Lung
Conditions: Official terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords:
carcinoma, non-small-cell lung* / diagnosis
carcinoma, non-small-cell lung* / genetics
precision medicine
lung neoplasms
neoplasms by site
registry
pathology, molecular
Study type:
Observational [Patient Registry]
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Other
Intervention name:
observational, non-interventional
Description:
observational, non-interventional
Summary:
Registry of the national Network Genomic Medicine Lung Cancer (nNGM), linking data on
molecular diagnostics, clinical characteristics, treatment patterns and outcomes of
subjects with non-small cell lung cancer (NSCLC) from 23 specialized cancer centres and
more than 400 general hospitals and oncological practices in Germany
Detailed description:
Within the national Network Genomic Medicine Lung Cancer (nNGM), comprehensive molecular
diagnostics and treatment recommendations are provided by 23 certified cancer centres
according to standardized procedures for patients with non-resectable NSCLC. More than
400 network partners across Germany (including hospitals and oncological practices)
report data on subsequent treatment and outcomes to the nNGM registry. Clinical outcomes
are continuously evaluated through analysis of data collected in a decentralized
registry. The nNGM registry records the patient journey and course of the disease from
first histologically confirmed diagnosis to death or loss to follow-up and comprises
detailed data on demographic and clinical characteristics, molecular diagnostics
(including comprehensive biomarker testing results), treatments (targeted therapy,
immunotherapy, chemotherapy, radiotherapy, best supportive care) and outcomes (overall
survival, response, disease progression, time to next treatment). Patients have been
actively involved throughout all stages of the design and running of the network and its
registry.
Criteria for eligibility:
Study pop:
Participants with histologically confirmed NSCLC are enrolled by 23 certified cancer
centres and more than 400 network partners (hospitals and oncological practices) across
Germany.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Age ≥ 18 years
- Histologically confirmed, locally advanced or metastatic NSCLC (Union for
International Cancer Control [UICC] stage IIIb/IV; non-resectable NSCLC)
- From 07/2023: histologically confirmed NSCLC stage Ib, II, III (UICC)
Exclusion Criteria:
- Missing written informed consent
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
University Hospital Cologne
Address:
City:
Cologne
Country:
Germany
Status:
Recruiting
Contact:
Last name:
Anna Rasokat
Email:
anna.rasokat@uk-koeln.de
Start date:
April 1, 2018
Completion date:
December 31, 2030
Lead sponsor:
Agency:
Prof. Dr. Juergen Wolf
Agency class:
Other
Collaborator:
Agency:
Charite University, Berlin, Germany
Agency class:
Other
Collaborator:
Agency:
Helios Klinikum Emil von Behring
Agency class:
Other
Collaborator:
Agency:
Vivantes Hospital Berlin Neukölln
Agency class:
Other
Collaborator:
Agency:
University Hospital Carl Gustav Carus
Agency class:
Other
Collaborator:
Agency:
Heinrich-Heine University, Duesseldorf
Agency class:
Other
Collaborator:
Agency:
University Hospital Erlangen
Agency class:
Other
Collaborator:
Agency:
University Hospital, Essen
Agency class:
Other
Collaborator:
Agency:
Goethe University
Agency class:
Other
Collaborator:
Agency:
University Hospital Freiburg
Agency class:
Other
Collaborator:
Agency:
University Hospital Giessen and Marburg
Agency class:
Other
Collaborator:
Agency:
University Hospital Halle (Saale)
Agency class:
Other
Collaborator:
Agency:
Universitätsklinikum Hamburg-Eppendorf
Agency class:
Other
Collaborator:
Agency:
University Hospital Heidelberg
Agency class:
Other
Collaborator:
Agency:
Klinikum Hanover-Siloah Hospital
Agency class:
Other
Collaborator:
Agency:
University Hospital, Bonn
Agency class:
Other
Collaborator:
Agency:
University Hospital Schleswig-Holstein
Agency class:
Other
Collaborator:
Agency:
Johannes Gutenberg University Mainz
Agency class:
Other
Collaborator:
Agency:
University Hospital Munich (LMU)
Agency class:
Other
Collaborator:
Agency:
University Hospital rechts der Isar Munich (TUM)
Agency class:
Other
Collaborator:
Agency:
Pius-Hospital Oldenburg
Agency class:
Other
Collaborator:
Agency:
University Hospital Regensburg
Agency class:
Other
Collaborator:
Agency:
University Hospital Tuebingen
Agency class:
Other
Collaborator:
Agency:
Robert Bosch Hospital Stuttgart
Agency class:
Other
Collaborator:
Agency:
University Hospital Ulm
Agency class:
Other
Collaborator:
Agency:
Wuerzburg University Hospital
Agency class:
Other
Collaborator:
Agency:
University Hospital of Cologne
Agency class:
Other
Source:
University of Cologne
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05934032
https://nngm.de
